Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 3/20 | 0.54 |
| ▸ | FPR2 | P25090 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 3/20 | 0.46 |
| ▸ | FBP1 | P09467 | 4/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28830687 | 0.88 | FPR3 (0.47) | FPR3FPR2SMN1; SMN2MAPK10FFAR2 | |
| SCHEMBL27739667 | 0.85 | FPR3 (0.47) | FPR3FPR2SMN1; SMN2MAPK10FFAR2 | |
| SCHEMBL4479801 | 0.83 | SMN1; SMN2 (0.56) | FPR2SMN1; SMN2MAPK10FFAR2NPC1 | |
| SCHEMBL5835491 | 0.83 | FPR2 (0.58) | FPR3FPR2SMN1; SMN2MAPK10FFAR2 | |
| SCHEMBL12241503 | 0.83 | RAB9A (0.52) | SMN1; SMN2NPC1PKMRAB9ACCNE1 | |
| SCHEMBL27819346 | 0.81 | CA1 (0.47) | FPR3FPR2CCNE1CDK2CA1 | |
| SCHEMBL20877512 | 0.81 | CA1 (0.47) | FPR3FPR2FFAR2CCNE1CDK2 | |
| SCHEMBL15921777 | 0.81 | CA1 (0.50) | FPR3FPR2CCNE1CDK2CA1 | |
| SCHEMBL13266901 | 0.81 | CA1 (0.47) | FPR3FPR2SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL640631 | 0.81 | FFAR2 (0.52) | FFAR2CCNE1CDK2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | SEED THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260116875-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR TUBULIN-TARGETED THERAPY IN THE TREATMENT OF CANCERS AND RELATED CONDITIONS | REGLAGENE INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4704836-A1 | HETEROAROMATIC INDOLESULFONAMIDES | Seed Therapeutics, Inc (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | GILEAD SCIENCES, INC. | 2026-01-22 | — | — | US | disclosed |
| EP-4673130-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR THE TREATMENT OF HEALTH CONDITIONS | Reglagene, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12502380-B2 | MrgprX2 antagonists for the treatment of inflammatory disorders | DERMIRA, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2007104034-A2 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-09-13 | — | — | US | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022114-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | POLK, POLQ, POLB | FPR3 3966/4885FPR2 3658/4885SMN1; SMN2 3686/4885 |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | CTNNB1, CTNND1, CTNNA1 | FPR3 4662/4885FPR2 4777/4885SMN1; SMN2 1222/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | FPR3 4662/4885FPR2 4777/4885SMN1; SMN2 1222/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | FPR3 390/4885FPR2 593/4885SMN1; SMN2 266/4885 |
| US-12502380-B2 | MrgprX2 antagonists for the treatment of inflammatory disorders | MRGPRX2, MRGPRX1, MRGPRX4 | FPR3 160/4885FPR2 43/4885SMN1; SMN2 3817/4885 |
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | DCAF1, DCAF15, DDX39B | FPR3 4477/4885FPR2 4717/4885SMN1; SMN2 1923/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | FPR3 1549/4885FPR2 589/4885SMN1; SMN2 3662/4885 |
| US-20260116875-A1 | COMPOSITIONS AND METHODS FOR MAKING AND USING SMALL MOLECULES FOR TUBULIN-TARGETED THERAPY IN THE TREATMENT OF CANCERS AND RELATED CONDITIONS | TUBB1, TUBB6, TUBB | FPR3 2637/4885FPR2 1653/4885SMN1; SMN2 280/4885 |
| US-20070213349-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | FPR3 4569/4885FPR2 4507/4885SMN1; SMN2 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.